News
Meet Aikido Pharma Inc’s Board of Directors
Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.
Robert J. Vander Zanden, Ph.D.
Dr. Robert J. Vander Zanden, Board Member since 2004, was elected Chairman of the Board in early 2009.
Tim Ledwick
Mr. Ledwick is currently the Chief Financial Officer of Management Health Solutions, a private equity-backed company that provides software solutions and services to hospitals focused on reducing costs through superior inventory management practices.
Greg Blattner
Greg Blattner is a Director at Agio, a progressive Managed IT and Cybersecurity Cervices Provider.
Anthony C. Hayes, Esq.
Anthony C. Hayes is the CEO of Aikido Pharma Inc., a NASDAQ-traded (ticker: AIKI) technology commercialization company.
Paul LeMire
Paul LeMire is a Managing Director of Day Hagan Asset Management where he is responsible for National Sales and Distribution.
Robert Dudley
Robert Dudley is the Eastern Division and Metropolitan NYC Regional Sales Manager for Select Sector SPDRs. *
More News
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 1080
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 1040
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 1081
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1505
Meet Aikido Pharma Inc’s Board of Directors
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 1125
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 1119
Artificial Intelligence Is Optimizing Drug Development
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 1150
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 1039
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 1197
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1282
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 1221
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1409
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 1029
Aikido Pharma Establishes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 933
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1558
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 1115
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 2007
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 1226
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
